已收盘 12-12 16:00:00 美东时间
-3.500
-4.74%
Minneapolis, MN, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ: SEZL) announced its inclusion in the S&P SmallCap 600 index, effective after market close on Dec. 12, 2025. This marks a significant milestone for the fintech company, highlighting its progress and setting the stage for future growth. Sezzle CEO Charlie Youakim emphasized the importance of this achievement in strengthening the company's foundation.
12-09 18:54
Shares of Mama’s Creations Inc (NASDAQ:MAMA) rose sharply in pre-market trading...
12-09 17:48
Sezzle shares are trading higher after the company reported better-than-expecte...
11-06 06:17
Sezzle (NASDAQ:SEZL) is looking for FY2026 Adj EPS of $4.35 vs $4.27 analyst estimate..
11-06 06:03
Sezzle (NASDAQ:SEZL) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.65 by 9.06 percent. This is a 44.9 percent increase over earnings of $0.49 per share from the same
11-06 05:04
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Sezzle, a leading buy now, pay later (BNPL) platform, is helping retailers capture more shoppers during the 2025 holiday season with tools like Sezzle Up, Price Comparison, and Delivery Protection. According to a Sezzle survey, 47% of shoppers are concerned about rising prices, and 78% prioritize payment flexibility. Over 60% of consumers have already begun holiday shopping. Sezzle’s ecosystem enables shoppers to build credit, save items, track p...
10-15 14:38
<br> <p>Sezzle Inc. announced the expansion of its merchant network with new partners across fashion, sporting goods, beauty, fitness, and digital content to accommodate the 2025 holiday shopping season. The platform aims to cater to price-sensitive consumers, particularly Gen Z, who are expected to reduce spending significantly. New collaborations include Cato Fashions, SCHEELS, Dermstore, and regional stores, alongside a partnership with the di...
10-07 12:30
今日重点评级关注:HC Wainwright & Co.:维持Microbot Medical"买入"评级,目标价从9美元升至12美元;Maxim Group:维持Neuphoria Therapeutics"买入"评级,目标价从18美元升至35美元
09-12 12:53